Feasibility of Providing a Purpose Renewal Intervention for Cancer Survivors Via Virtual Groups (CC-V)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55447
- Abbott Northwestern Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to attend intervention sessions for 9 weeks on Monday or Tuesday afternoons (4:30 - 6:30 pm) starting Monday, April 5, 2021
- 25 years of age or older
- Completed chemotherapy and/or radiation treatment for Stage 0, 1, 2, or 3 breast cancer at least 2 months prior to participating in the Compass Course intervention
- English speaking
- Graduated from high school
- Able to see, hear, speak (with or without assistive devices)
- Able to provide own transportation to sessions
- Willing and able to commit to attend all 8 intervention sessions
- Access to computer or tablet and adequate internet connection to participate in video conference
Exclusion Criteria:
- Stage 4 breast cancer or any other cancer
- Actively receiving chemotherapy or radiation treatments for cancer. (However, patients may be on Herceptin and/or endocrine treatment and participate in the study.)
- History of neurologic disorder (such as stroke or brain injury) with residual impairments that likely interfere with learning
- Any medical condition (physical or mental health) that interferes with the performance of everyday activities and roles.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Compass Course
Virtual Compass Course
|
The Compass Course is an 8-session group course designed to address purpose in life of those with Breast Cancer.
Enrollment in this arm will involve participation in the Compass Course virtually.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Scales of Psychological Wellbeing
Time Frame: Through Study Completion (about 4 Months)
|
A widely-used self-report questionnaire that was designed to measure 6 theoretically motivated dimensions of psychological well-being (autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, self-acceptance).
|
Through Study Completion (about 4 Months)
|
|
Change in Meaning in Life Questionnaire
Time Frame: Through Study Completion (about 4 Months)
|
A 10-item questionnaire designed to measure 2 dimensions of meaning in life: Presence of Meaning (how much respondents feel their lives have meaning) and Search for Meaning (how much respondents strive to find meaning and understanding in their lives).
|
Through Study Completion (about 4 Months)
|
|
Change in Engagement in Meaningful Activities survey
Time Frame: Through Study Completion (about 4 Months)
|
A 12-item self-report questionnaire designed to measure the extent to which a person experiences meaningfulness in his/her daily life activities.
|
Through Study Completion (about 4 Months)
|
|
Change in Purpose Status Question
Time Frame: Through Study Completion (about 4 Months)
|
A single forced-choice self-report screener question that we developed in order to characterize existential distress related to purpose in life.
|
Through Study Completion (about 4 Months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Beck Depression Inventory -- II
Time Frame: Through Study Completion (about 4 Months)
|
A 21-question, widely-used self-report rating inventory that measures characteristic attitudes and symptoms of depression.
|
Through Study Completion (about 4 Months)
|
|
Change in State-Trait Anxiety Inventory
Time Frame: Through Study Completion (about 4 Months)
|
A self-report questionnaire composed of 20 state and 20 trait statements related to anxiety.
We will use the 20-item State inventory (1-4 scale).
|
Through Study Completion (about 4 Months)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mary V Radomski, OTR/L, PhD, Senior Scientific Advisor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CKRC2021-CCV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
NCT01372579UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer
-
NCT01292083WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
NCT07331506RecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating Ductal Carcinoma
-
NCT00618657CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast Cancer
-
NCT00407888CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast Cancer
-
NCT00986609CompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer
-
NCT02566408CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer
-
NCT00513695CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer
-
NCT01234532TerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer
-
NCT00559507CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer
Clinical Trials on Compass Course
-
NCT05780658Completed
-
NCT02384642CompletedDomestic Violence | Sexual Assault | Interpersonal Relations | Marital Status
-
NCT01816061CompletedTraumatic Brain Injury | Post-Traumatic Stress Disorder
-
NCT06222359Not yet recruitingDepression | Multiple Sclerosis | Anxiety
-
NCT05140551CompletedDepression | Quality of Life | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Diabetes Mellitus, Type 1 | Anxiety | Loneliness | Distress, Emotional | Diabetes Distress
-
NCT05330299RecruitingPsychological Distress | IBD | Treatment of Illness-related Distress in IBD
-
NCT05081947CompletedDepression | Heart Failure | Anxiety